XML 31 R20.htm IDEA: XBRL DOCUMENT v3.25.1
Segment reporting
 6 Months Ended
Feb. 28, 2025
Segment Reporting [Abstract]  
Segment reporting Segment reporting
The Company is aligned into three reportable segments: U.S. Retail Pharmacy, International and U.S. Healthcare.

The operating segments have been identified based on the financial data utilized by the Company’s Chief Executive Officer (the chief operating decision maker) to assess segment performance and allocate resources among the Company’s operating segments. The chief operating decision maker uses adjusted operating income to assess segment profitability. The chief operating decision maker does not use total assets by segment to make decisions regarding resources; therefore, the total asset disclosure by segment has not been included.

U.S. Retail Pharmacy
The Company’s U.S. Retail Pharmacy segment includes the Walgreens business which is comprised of the operations of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and its equity method investment in Cencora. Sales for the segment are principally derived from the sale of prescription drugs and a wide assortment of retail products, including health and wellness, beauty, personal care and consumables and general merchandise.

International
The Company’s International segment consists of pharmacy-led health and beauty retail businesses outside the U.S. and a pharmaceutical wholesaling and distribution business in Germany. Pharmacy-led health and beauty retail businesses include Boots branded stores in the UK, the Republic of Ireland and Thailand, and the Benavides brand in Mexico. Sales for these businesses are principally derived from the sale of prescription drugs and health and wellness, beauty, personal care and other consumer products.
U.S. Healthcare
The Company’s U.S. Healthcare segment engages consumers through a personalized, omni-channel experience across the care journey. The U.S. Healthcare segment delivers improved health outcomes and lower costs for payors and providers by delivering care through owned and partnered assets.

The U.S. Healthcare segment currently consists of a majority position in VillageMD, a national provider of value-based care with primary, multi-specialty, and urgent care providers serving patients in traditional clinic settings, in patients’ homes and online appointments; as well as Shields Health Solutions Parent, LLC (“Shields”), a specialty pharmacy integrator and accelerator for hospitals; and CareCentrix, a participant in the post-acute and home care management sectors, and the Walgreens Health organic business that contracts with different participants in the healthcare ecosystem to provide commercial and clinical healthcare services.

The results of operations for reportable segments include procurement benefits. Corporate-related overhead costs are not allocated to reportable segments and are reported in “Corporate and Other”.

The following table reflects results of operations of the Company’s reportable segments (in millions):
Three months endedSix months ended
February 28, 2025February 29, 2024February 28, 2025February 29, 2024
Sales:
U.S. Retail Pharmacy
Pharmacy$23,432 $21,508 $48,143 $43,892 
Retail6,948 7,353 13,103 13,913 
Total$30,380 $28,861 $61,246 $57,805 
International
Pharmacy$837 $898 $1,749 $1,824 
Retail2,182 2,158 4,298 4,090 
Wholesale3,041 2,966 6,438 5,940 
Total$6,060 $6,022 $12,485 $11,854 
U.S. Healthcare$2,152 $2,176 $4,325 $4,107 
Corporate and Other 1
$(4)$(6)$(8)$(6)
Walgreens Boots Alliance, Inc.$38,588 $37,052 $78,048 $73,760 
Adjusted operating income:
U.S. Retail Pharmacy$487 $752 $928 $1,446 
International234 245 401 387 
U.S. Healthcare117 (34)142 (129)
Corporate and Other(52)(63)(93)(117)
Walgreens Boots Alliance, Inc.$785 $900 $1,378 $1,588 

1.Includes certain eliminations.
The following table reconciles adjusted operating income to operating loss (in millions):
Three months endedSix months ended
February 28, 2025February 29, 2024February 28, 2025February 29, 2024
Adjusted operating income (Non-GAAP measure)$785 $900 $1,378 $1,588 
Impairment of goodwill, intangibles and long-lived assets(5,343)(13,090)(5,343)(13,090)
Acquisition-related amortization(250)(270)(520)(545)
Acquisition and disposition-related costs(94)(249)(198)(412)
Certain legal and regulatory accruals and settlements(548)(242)(607)(324)
Transformational cost management(3)(197)12 (306)
Adjustments to equity earnings in Cencora(33)(22)(109)(72)
LIFO provision(12)— (24)(48)
Footprint optimization(68)— (400)— 
Operating loss (GAAP)$(5,567)$(13,171)$(5,812)$(13,209)